Genetic Predisposition for Breast Cancer & Management of BRCA1/2 Mutation Carriers

Inherited mutations in the BRCA1 and BRCA2 genes are among the most well-known genetic risk factors for breast and ovarian cancers. These high-penetrance variants can increase a woman’s lifetime risk of developing breast cancer up to 72%, and are also associated with elevated risks for ovarian, pancreatic, and prostate cancers. This CME/CE course offers a deep dive into the genetics, risk stratification, and evolving evidence surrounding BRCA1 and BRCA2 pathogenic variants.

Participants will first gain a foundational understanding of the molecular biology behind BRCA gene function, the difference between hereditary and familial breast cancer syndromes, and the inheritance patterns relevant to family history assessments. The course then transitions to a review of evidence-based surveillance recommendations, such as MRI and mammogram screening protocols beginning as early as age 25, and the role of genetic counseling.

Key preventive strategies are covered in detail, including prophylactic mastectomy and salpingo-oophorectomy, along with less invasive options like lifestyle modifications and chemoprevention. Emerging therapies such as PARP inhibitors are discussed in the context of both primary prevention and treatment in newly diagnosed BRCA-positive breast cancer patients.

The session further addresses complex management decisions for patients already diagnosed with breast cancer, with special attention to systemic treatment considerations, surgical planning, and the evolving debate around contralateral mastectomy. Patient-specific variables, including menopausal status, personal risk tolerance, and fertility considerations, contextualize decision-making.

Designed for healthcare professionals involved in oncology, women’s health, genetics, and survivorship care, this course provides critical insights into the personalized management of BRCA mutation carriers. By integrating clinical guidelines with the latest advances in genomics and therapeutics, the course supports providers in delivering evidence-based, patient-centered care.

Learning Objectives

After completing this activity, learners will be able to:

• Explain the genetic mechanisms and cancer risk associated with BRCA1 and BRCA2 pathogenic variants.
• Describe current evidence-based screening protocols and preventive strategies for individuals with BRCA mutations.
• Apply evidence-based treatment approaches, including surgical and systemic therapies, for patients with BRCA-associated breast cancer.

Who Should Do This Course?

This course is intended for:

• Medical oncologists and surgical oncologists managing hereditary breast cancer patients.
• Obstetricians and gynecologists involved in cancer prevention, risk assessment, and genetic testing referrals.
• Primary care physicians and internists who oversee long-term surveillance of high-risk women.
• Clinical nurse specialists, oncology nurses, and reproductive health providers who support patients through screening, treatment, and survivorship.
• Genetic counselors and reproductive endocrinologists focusing on hereditary cancer syndromes and fertility preservation.

Did You Know?

• Approximately 1 in 400 individuals in the general population carries a BRCA1 or BRCA2 mutation. (CDC, 2023)
• Up to 10% of breast cancer cases are hereditary, with BRCA mutations being the most common cause. (National Cancer Institute, 2022)
• BRCA-related breast cancers often present at a younger age and are more likely to be triple-negative. (JAMA Oncology, 2021)
• Risk-reducing mastectomy lowers the chance of breast cancer in BRCA carriers by up to 95%. (NEJM, 2020)
• PARP inhibitors can delay recurrence in early-stage BRCA-positive breast cancer by up to 42%. (OlympiA Trial, 2021)